ASA. S. Starovoitova

A. S. Starovoitova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


A. S. Starovoitova has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Preferential drug program for patients within the federal project for control of cardiovascular diseases: implementation strategy, results and prospects

    by E. G. Kamkin, E. V. Karakulina, E. M. Astapenko, V. A. Gulshina, A. A. Moskalev, A. S. Starovoytova, E. P. Mazygula, Z. N. Tautova, N. E. Zvartau, E. A. Medvedeva, et al.

    A serious barrier to the widespread practical implementation of evidence therapy for cardiovascular diseases is financial constraints, which exacerbate low patient complience and affect inequality in cardiovascular health indicators population, increasing morbidity and mortality. At the level of healthcare systems in different countries, drug provision is recognized as an effective tool for increasing patient adherence to treatment and improving clinical outcomes. The problematic article discusses the preferential drug program within the federal project for control of cardiovascular diseases. The key principles for forming priority groups, mechanisms and stages of program implementation are outlined. Monitoring the program’s effectiveness made it possible to identify reserves and prospects for its further strategic development.


  • Open Access

    Childhood acute myeloid leukemia with the t(8;16)(p11;p13) translocation

    by V. E. Matveev, I. I. Kalinina, U. N. Petrova, M. E. Dubrovina, A. S. Starovoitova, A. A. Maschan

    Acute myeloid leukemia is a clonal systemic disease of the hematologic system, which includes heterogeneous group of diseases. Therefore optimization of methods of treatment of this pathology is an important task. More than 1% of AML with rare translocations can not be strictly divided into risk groups. There are also discrepancies between different researchers’ data on the same cytogenetic abnormalities. In this article we present the experience of diagnostics and therapy of the patient with the rare sub-type of AML with the t(8;16)(p11;p13) translocation in Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology. The patient received high-dose chemotherapy and allogeneic hematopoietic stem cell transplant. According to catamnesis the child (1.5 years) has been in the clinico-hematological and cytogenetic remission.